EUFOREA pocket guide on the diagnosis and management of asthma: An educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients.
暂无分享,去创建一个
I. Pavord | V. Backer | D. Ryan | G. Scadding | P. Hellings | P. Panzner | R. Djukanović | A. Spanevello | W. Busse | S. Loukides | M. Gaga | N. Hanania | I. Stříž | S. Quirce | L. Heaney | L. Bjermer | Z. Diamant | H. Pité | P. Bakakos | B. Thio | M. Vašáková | H. Stenberg | D. Antolín‐Amérigo | S. Assaf | A. Bobcakova | W. Fokkens | J. Kappen | Diego M. Conti | S. Lau | M. van Maaren | M. Jeseňák | E. Van Staeyen | D. Conti
[1] S. Loukides,et al. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis , 2023, Clinical science.
[2] D. Strachan,et al. Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross-sectional study , 2023, The Lancet. Global health.
[3] A. Muraro,et al. Allergen immunotherapy for allergic asthma - The future seems bright. , 2023, Respiratory medicine.
[4] A. Leunig,et al. The EUFOREA pocket guide for chronic rhinosinusitis. , 2022, Rhinology.
[5] G. Koppelman,et al. Biologic Therapies for Severe Asthma. , 2022, The New England journal of medicine.
[6] I. Pavord,et al. Choosing a Biologic For Patients With Severe Asthma , 2021, The Journal of Allergy and Clinical Immunology: In Practice.
[7] R. Pawankar,et al. Allergic Rhinitis in Childhood and the New EUFOREA Algorithm , 2021, Frontiers in Allergy.
[8] B. Lipworth,et al. Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline , 2021, American journal of respiratory and critical care medicine.
[9] D. Ryan,et al. EUFOREA treatment algorithm for allergic rhinitis , 2020, Rhinology journal.
[10] A. Waljee,et al. Burst Case Scenario: Why Shorter May Not Be Any Better When It Comes to Corticosteroids , 2020, Annals of Internal Medicine.
[11] R. Gerth van Wijk,et al. Toward clinically applicable biomarkers for asthma: An EAACI position paper , 2019, Allergy.
[12] D. Ryan,et al. ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions , 2019, European Respiratory Journal.
[13] S. Loukides,et al. Towards precision medicine in severe asthma: Treatment algorithms based on treatable traits. , 2018, Respiratory medicine.
[14] A. Sheikh,et al. EAACI guidelines on allergen immunotherapy: Executive statement , 2018, Allergy.
[15] D. Postma,et al. Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: a cross-sectional analysis. , 2006, Respiratory medicine.
[16] I. Pavord,et al. Tackling ‘People Remodelling’ in Corticosteroid-dependent Asthma with Type-2 Targeting Biologics and a Formal Corticosteroid Weaning Protocol , 2022, US Respiratory & Pulmonary Diseases.
[17] N. Hanania,et al. Precision medicine and treatable traits in chronic airway diseases - where do we stand? , 2019, Current opinion in pulmonary medicine.